当前位置: X-MOL 学术Horm. Res. Paediatr. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study
Hormone Research in Paediatrics ( IF 3.2 ) Pub Date : 2021-03-26 , DOI: 10.1159/000513702
Laetitia Martinerie 1, 2 , Jacques de Mouzon 3 , Joelle Blumberg 4 , Luigi di Nicola 5 , Pascal Maisonobe 4 , Jean-Claude Carel 1, 2 ,
Affiliation  

Background: Gonadotropin-releasing hormone analogues (GnRHa) administered as depot formulations are the standard of care for children with central precocious puberty (CPP). Puberty resumes after treatment discontinuation, but little is known concerning fertility in women who have been treated with GnRHa for CPP during childhood. Methods: The PREFER (PREcocious puberty, FERtility) study prospectively analysed fertility, via a series of questionnaires, in women treated during childhood with triptorelin (depot formulation) for CPP. Co-primary endpoints were the proportion of women wanting a pregnancy any time before study inclusion and during the follow-up period but not pregnant 6 and 12 months after stopping contraception and the waiting time to pregnancy (WTP). Results: A total of 574 women were identified, and 194 women were included in the analysis. Although there were not enough data for primary endpoint assessment, few women (1.7%) reported issues with fertility or were unable to become pregnant despite trying to conceive. Most pregnancies (84.4%, 95% CI [67.2–94.7%]) occurred within 1 year of trying to conceive, in line with the WTP for women without previous CPP. Conclusion: The results, based on a limited sample of patients, suggest that CPP treated with triptorelin does not negatively impact women’s fertility in adulthood. These results need to be consolidated with a subsequent study performed when these women will have reached their mid-thirties.
Horm Res Paediatr


中文翻译:

儿童期用曲普瑞林(长效制剂)治疗中枢性性早熟的妇女的生育能力:首选研究

背景:作为长效制剂给药的促性腺激素释放激素类似物 (GnRHa) 是中枢性性早熟 (CPP) 儿童的标准护理。停止治疗后青春期恢复,但对于在儿童期接受 GnRHa 治疗 CPP 的女性的生育能力知之甚少。方法: PREFER(PREcocious puberty,FERtility)研究通过一系列问卷调查前瞻性地分析了在儿童期使用曲普瑞林(长效制剂)治疗 CPP 的女性的生育能力。共同主要终点是在研究纳入前的任何时间和随访期间想要怀孕但在停止避孕后 6 个月和 12 个月以及等待怀孕时间 (WTP) 后未怀孕的女性比例。结果:共确定了 574 名女性,其中 194 名女性被纳入分析。尽管没有足够的数据用于主要终点评估,但很少有女性 (1.7%) 报告了生育问题或尽管试图怀孕但仍无法怀孕。大多数怀孕 (84.4%, 95% CI [67.2–94.7%]) 发生在试图怀孕的 1 年内,这与之前没有 CPP 的女性的 WTP 一致。结论:基于有限的患者样本的结果表明,曲普瑞林治疗的 CPP 不会对成年女性的生育能力产生负面影响。这些结果需要与这些女性年满 30 岁时进行的后续研究相结合。
儿科荷尔蒙
更新日期:2021-03-26
down
wechat
bug